SCYNEXIS, Inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. Our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. We plan to leverage this expertise in human and animal drug development to pursue the development of our proprietary compounds. We are developing our lead product candidate, SCY-078, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans. In addition, we have clinical and preclinical programs based on the use of cyclophilin inhibitors to treat viral diseases. Leveraging our unique expertise in parasitic infections and drug discovery, we are developing a number of technologies for the benefit of key animal health markets. Our animal health group currently has three compounds in development with major partners and one drug in Phase 1 studies resulting from a collaboration funded by the Bill & Melinda Gates Foundation.